Thalidomide in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Phase II trial to study the effectiveness of thalidomide in treating patients with recurrent
or metastatic head and neck cancer. Thalidomide may stop the growth of head and neck cancer
by stopping blood flow to the tumor.